<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00984997</url>
  </required_header>
  <id_info>
    <org_study_id>ID92-038</org_study_id>
    <nct_id>NCT00984997</nct_id>
  </id_info>
  <brief_title>Combined Modality Treatment for Resectable Non-Small Cell Superior Sulcus Tumors</brief_title>
  <official_title>Phase II Study of Combined Modality Treatment for Resectable Non-Small Cell Superior Sulcus Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. To determine the outcome of patients with potentially resectable superior sulcus tumors
           of non-small cell histology treated by surgery followed by accelerated radiation therapy
           and chemotherapy.

        2. To evaluate toxicity, the initial local-regional control rate, sites of and time to
           local and distant failures.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eligible (surgically resectable and medically operable) patients will have surgery followed
      by radiation therapy, given twice daily, for 5 weeks if margins are negative and for 5-1/2
      weeks for positive margins. Grossly positive margins can be treated by brachytherapy followed
      by external radiotherapy.

      Concomitant chemotherapy consisting of cisplatin given intravenously on days 1 and 8, and
      etoposide taken by mouth 30-60 minutes prior to each radiotherapy treatment x the first 10
      days. The cycle will be repeated start day 29.

      If the patients are considered to have no evidence of disease in one month after completion
      of chemotherapy, optional prophylactic radiotherapy to the brain will be give in 10 fractions
      once daily for 2 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 1993</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">June 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rates of Locoregional control (LRC) [Response] Following Surgery and Accelerated Radiation Therapy/Chemotherapy</measure>
    <time_frame>Assessed from one month after completion of chemotherapy to year 10</time_frame>
    <description>Locoregional control (LRC) defined as disease non-recurrence in a localized area for patients with resectable superior sulcus tumors treated with surgical resection followed by adjuvant chemoradiation. LRC measured as percentage of participants without recurrence at rates of local control as measured Years 2, 5, and 10.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Surgery + Radiotherapy + Chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Surgery followed by radiotherapy and chemotherapy started at the beginning of radiotherapy. Segmentectomy or lobectomy with en bloc resection of the involved chest. Radiation therapy consists of 60 Gy in 50 fractions for negative margins, or 64.8 Gy in 54 fractions for positive margins, at 1.2 Gy per fraction, 2 fractions per day, 5 days per week. Cisplatin 50 mg/M^2 given intravenously on days 1 and 8; the cycle will be repeated beginning on day 29.
Etoposide given by mouth 30-60 minutes prior to each administration of radiotherapy, on days 1-5 and days 8-12; the cycle will be repeated beginning day 29. Prophylactic Cranial Irradiation 25 Gy in 10 fractions of 2.5 Gy, 1 fraction per day, will be given at the completion of chest irradiation, and is optional.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Surgery</intervention_name>
    <description>Segmentectomy or lobectomy with en bloc resection of the involved chest.</description>
    <arm_group_label>Surgery + Radiotherapy + Chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Chest Irradiation</intervention_name>
    <description>Radiation therapy consists of 60 Gy in 50 fractions for negative margins, or 64.8 Gy in 54 fractions for positive margins, at 1.2 Gy per fraction, 2 fractions per day, 5 days per week.</description>
    <arm_group_label>Surgery + Radiotherapy + Chemotherapy</arm_group_label>
    <other_name>Radiotherapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>50 mg/M^2 given intravenously on days 1 and 8; the cycle will be repeated beginning on day 29.</description>
    <arm_group_label>Surgery + Radiotherapy + Chemotherapy</arm_group_label>
    <other_name>Platinol</other_name>
    <other_name>CDDP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
    <description>given by mouth 30-60 minutes prior to each administration of radiotherapy, on days 1-5 and days 8-12; the cycle will be repeated beginning day 29.</description>
    <arm_group_label>Surgery + Radiotherapy + Chemotherapy</arm_group_label>
    <other_name>VePesid</other_name>
    <other_name>VP-16</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Prophylactic Cranial Irradiation</intervention_name>
    <description>25 Gy in 10 fractions of 2.5 Gy, 1 fraction per day, will be given at the completion of chest irradiation, and is optional.</description>
    <arm_group_label>Surgery + Radiotherapy + Chemotherapy</arm_group_label>
    <other_name>PCI</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. No previous treatment.

          2. Tumor must be resectable.

          3. &gt;/= 18 and &lt;/= 70 years of age.

          4. Zubrod performance status &lt;/= or higher performance status if based only on pain.

          5. Must have adequate bone marrow, liver and renal function as defined in 3.6.

        Exclusion Criteria:

          1. Cytological or histological proof of N3 disease.

          2. Evidence of metastatic disease to distant sites.

          3. Patients with impending cord compression will be ineligible.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ritsuko Komaki, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>University of Texas MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 24, 2009</study_first_submitted>
  <study_first_submitted_qc>September 24, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 25, 2009</study_first_posted>
  <last_update_submitted>June 29, 2016</last_update_submitted>
  <last_update_submitted_qc>June 29, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 30, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Superior Sulcus Tumor</keyword>
  <keyword>Lung Cancer</keyword>
  <keyword>Non-Small Cell</keyword>
  <keyword>Multimodality Treatment</keyword>
  <keyword>Surgery</keyword>
  <keyword>Segmentectomy</keyword>
  <keyword>Lobectomy</keyword>
  <keyword>Cisplatin</keyword>
  <keyword>CDDP</keyword>
  <keyword>Etoposide</keyword>
  <keyword>VP-16</keyword>
  <keyword>VePesid</keyword>
  <keyword>Radiation Therapy</keyword>
  <keyword>Radiotherapy</keyword>
  <keyword>Chest Irradiation</keyword>
  <keyword>Prophylactic Cranial Irradiation</keyword>
  <keyword>PCI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancoast Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Etoposide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

